Novavax Gets Expanded Vaccine EUA From FDA for Ages 12-17

Dow Jones2022-08-20

Novavax Inc.'s Covid-19 vaccine, which became available in the U.S. in July for adults, has received expanded emergency use authorization from the Food and Drug Administration, for people ages 12 through 17.

Doses will be available upon a favorable policy recommendation from the Centers for Disease Control and Prevention.

Novavax said the expanded EUA will "hopefully help increase vaccination rates, particularly as we prepare for ongoing surges of COVID-19 with the start of fall and the back-to-school season."

The company hopes its vaccine "may have a special role in adolescent vaccination based on parents' and caregivers' familiarity with protein-based vaccines used in other disease areas."

Novavax, which lowered 2022 sales guidance on Aug. 8, received New Zealand expanded provisional vaccine approval this week for ages 12 through 17.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • robot1234
    2022-08-21
    robot1234
    FDA authorizes emergency use for Novavax Covid-19 vaccine for ages 12 to 17. Novavax announced on Saturday that its Covid-19 vaccine has been authorized for emergency use by the Food and Drug Administration for adolescents between the ages of 12 and 17.In July, Novavax’s two-dose Covid-19 vaccine for adults ages 18 and over got its emergency approval from the FDA.Having more vaccine options for adults and children will “hopefully help increase vaccination rates, particularly as we prepare for ongoing surges of Covid-19 with the start of fall and the back-to-school season,” Stanley C. Erck, president and CEO of Novavax, said in a statement.Dr. Peter Marks, a senior FDA official, has said that Novavax’s vaccine would potentially appeal to unvaccinated people who would prefer a shot that is n
  • AhBart
    2022-08-20
    AhBart
    Great job 👏🏾 
  • 来人
    2022-08-20
    来人
    Up
  • blessed_1
    2022-08-20
    blessed_1
    Ok
  • Kimoqi
    2022-08-20
    Kimoqi
    Ok
  • RS142
    2022-08-20
    RS142
    Good
Leave a comment
15